KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
Minoxidil, finasteride, and dutasteride are effective for hair loss. Alternative treatments like oils and supplements are less effective and more costly.
The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.
The conversation is about a person considering making their own topical finasteride to avoid side effects from oral use. They discuss potential methods and ingredients, including cayenne pepper extract, rosemary, and coconut oil, and seek advice on effectiveness and alternatives like light therapy or dermarolling.
A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.
The conversation is about obtaining custom-compounded topical finasteride in Germany due to side effects from oral finasteride. The user seeks a lower concentration solution separate from minoxidil, and others suggest self-mixing or trying alternatives like dutasteride.
The conversation is about using a topical solution of latanoprost and minoxidil for hair loss, with concerns about side effects due to a history of gynecomastia. The user is considering this treatment instead of finasteride and is seeking experiences from others.
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
A user questions if a topical compound with finasteride, dutasteride, minoxidil, retinoic acid, caffeine, and triamcinolone is excessive for hair loss treatment. Another user shares their experience using topical finasteride without issues and notes that alternating finasteride and dutasteride is common.
The conversation is about DIY Dutasteride mesotherapy for hair loss, focusing on creating an injectable treatment to target the scalp and limit side effects. The user seeks feedback on enhancing the treatment with additional ingredients.
Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.
A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
User is asking for progress on hair regrowth after 6 months of using oral finasteride and minoxidil tablets. Replies suggest good results and recommend using dutasteride instead of finasteride for severe hair loss.
A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.
The user experienced significant hair regrowth after 60 days using a topical compound of Minoxidil, Finasteride, and Tretinoin, along with oral Minoxidil and Finasteride. They reported initial side effects but saw improvement in hair density and appearance.
The conversation discusses microneedling techniques and the use of Minoxidil, copper peptides, EGF, FGF, ceramides, and hydration serums to enhance hair growth. It explores optimizing scalp conditions and the potential benefits of various compounds in conjunction with microneedling.
The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
A user ordered a compounded medication from Musely containing Dutasteride, Minoxidil, and other vitamins, expressing concerns about its contents and effectiveness. Another user shared their experience with side effects but noted hair regrowth, while adjusting the dosage to reduce symptoms.
A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.